ÂÜÀòÂÒÂ×

Dr. William Young is a Senior Advisor at Blackstone Life Sciences. He currently serves as the Lead Director at Theravance (NASDAQ:TBPH), Chairman of the Board of Nanostring (NASDAQ: NSTG) and on the Board of Directors of Praxis Medicine (NASDAQ: PRAX) and Autolus Therapeutics (NASDAQ: AUTL). Previously he was Chairman of the Board of Biogen (NASDAQ: BIIB).

Young previously served as CEO of Monogram Biosciences, a leader in personalized medicine, from 1999 through to the sale of the company to LabCorp in 2009.

Prior to Monogram, Young was at Genentech since 1980 at positions of increasing responsibility, including COO, responsible for all of the biotechnology company's development, operations and commercial functions. Prior to Genentech, he was at Eli Lilly and Company for 14 years.

Young received his Bachelor's degree in Chemical Engineering from Purdue University, his MBA from Indiana University and an Honorary Doctorate in Engineering from Purdue University. In 1993 he was elected to the National Academy of Engineering for his leadership in research, development and manufacturing of recombinant proteins using recombinant DNA technology.